Pharmacogenetics of drug response in Parkinson's disease

References

• de Rijk MC, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: EUROPARKINSON collaborative study. J Neurol Neurosurg Psychiatry 1997;62:10–5.
   PubMed Web of Science ®Google Scholar
• Robillard MJ, Federico AC, Tairyan K, et al. Untapped ethical resources for neurodegeneration research. BMC Med Ethics 2011;12:9.
   PubMed Web of Science ®Google Scholar
• Klockgether T. Parkinson's disease: Clinical aspects. Cell Tissue Res 2004;318:115–20.
   PubMed Web of Science ®Google Scholar
• Sulzer D. Multiple hit hypothesis for dopamine neuron loss in Parkinson's disease. Trends Neurosci 2007;30:244–50.
   PubMed Web of Science ®Google Scholar
• Wolters EC, Braak H. Parkinson's disease: premotor clinico-pathological correlations. J Neural Transm 2006;70(Suppl): 309–19.
   Google Scholar
• Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. JAMA 1999;281:341–6.
   PubMed Web of Science ®Google Scholar
• Sampaio-Marques B, Felgueiras C, Silva A, et al. SNCA (α–synuclein)–induced toxicity in yeast cells is dependent on sirtuin 2 (Sir2)–mediated mitophagy. Autophagy 2012;8:1494–509.
   PubMed Web of Science ®Google Scholar
• Kilarski LL, Pearson JP, Newsway V, et al. Systematic Review and UK–Based Study of PARK2 (parkin), PINK1, PARK7 (DJ–1) and LRRK2 in early–onset Parkinson's disease. Mov Disord 2012;27:1522–9.
   PubMed Web of Science ®Google Scholar
• Torkaman-Boutorabi A, Shahidi GA, et al. The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease. Acta Neurobiol Exp (Wars) 2012;72:272–82.
   PubMed Web of Science ®Google Scholar
• Białecka M, Droździk M, Kłodowska-Duda G, et al. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease. Acta Neurol Scand 2004;110:260–6.
   PubMed Web of Science ®Google Scholar
• Nalls MA, Pankratz N, Lill CM, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat Genet 2014 [Epub ahead of print]
   Google Scholar
• Singh M, Khan AJ, Shah PP, et al. Polymorphism in environment responsive genes and association with Parkinson disease. Mol Cell Biochem 2008;312:131–8.
   PubMed Web of Science ®Google Scholar
• Wang D, Zhai JX, Zhang LM, et al. Null genotype of GSTT1 contributes to increased Parkinson's disease risk in Caucasians: evidence from a meta-analysis. Mol Biol Rep 2014 [Epub ahead of print]
   Web of Science ®Google Scholar
• Wang T, Wang B. Association between Glutathione S-transferase M1/Glutathione S-transferase T1 polymorphisms and Parkinson's disease: a meta-analysis. J Neurol Sci 2014;338:65–70.
   PubMed Web of Science ®Google Scholar
• Hao H, Shao M, An J, et al. Chinese Parkinson Study Group. Association of Catechol-O-Methyltransferase and monoamine oxidase B gene polymorphisms with motor complications in parkinson's disease in a Chinese population. Parkinsonism Relat Disord. 2014 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Sun YX, Wang XH, Xu AH, et al. Functional polymorphisms of the MAO gene with Parkinson disease susceptibility: A meta-analysis. J Neurol Sci. 2014 [Epub ahead of print]
   Web of Science ®Google Scholar
• Swen JJ, Huizinga TW, Gelderblom H, et al. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med 2007;4:E209
   PubMed Web of Science ®Google Scholar
• Drozdzik M, Monika Bialecka M, Kurzawski M. Pharmacogenetics of Parkinson's Disease –Through Mechanisms of drug actions. Current Genomics 2013;14:568–77.
   PubMed Web of Science ®Google Scholar
• Arbouw ME, van Vugt JP, Egberts TC, et al. Pharmacogenetics of antiparkinsonian drug treatment: a systematic review. Pharmacogenomics 2007;8:159–76.
   PubMed Web of Science ®Google Scholar
• Bialecka M, Kurzawski M, Klodowska-Duda G, et al. The association of functional catechol–O–methyltransferase haplotypes with risk of Parkinson's disease, L–DOPA treatment response, and complications. Pharmacogenetics & Genomics 2008;18:815–21.
   PubMed Web of Science ®Google Scholar
• Gilman C, McSweeney C, Mao Y. The Applications of Pharmacogenomics to Neurological Disorders. Curr Mol Med. 2014 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Agúndez JA, García-Martín E, Alonso-Navarro H, et al. Anti-Parkinson's disease drugs and pharmacogenetic considerations. Expert Opin Drug Metab Toxicol 2013;9:859–74.
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Korczyn AD, et al. Study Group: A five–year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or L–DOPA. N Engl J Med 2000;342:1484–91.
   PubMed Web of Science ®Google Scholar
• Lee JY, Cho J, Lee EK, et al. Differential genetic susceptibility in disphasic and peak–dose dyskinesias in parkinson's disease. J Mov Disord 2011;26:73–9.
   PubMed Web of Science ®Google Scholar
• Corvol JC, Bonnet C, Charbonnier–Beaupel F, et al. The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. Ann Neurol 2011;69:111–8.
   PubMed Web of Science ®Google Scholar
• Contin M, Martinelli P, Mochi M, et al. Genetic polymorphism of catechol–O–methyltransferase and levodopa pharmacokinetic–pharmacodynamic pattern in patients with Parkinson's disease. Mov Disord 2005;20:734–9.
   PubMed Web of Science ®Google Scholar
• Kalinderi K, Fidani L, Katsarou Z, et al. Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease. Int J Clin Pract 2011;65:1289–94.
   PubMed Web of Science ®Google Scholar
• Hoogland J, de Bie RM, Williams-Gray CH, et al. Catechol–O–methyltransferase val158met and cognitive function in Parkinson's disease. J Mov Disord 2010;25:2550–54.
   PubMed Web of Science ®Google Scholar
• Lee MS, Lyoo CH, Ulmanen I, et al. Genotypes of catechol-O-methyltransferase and response to levodopa treatment in patients with Parkinson's disease. Neurosci Lett 2001;298:131–4.
   PubMed Web of Science ®Google Scholar
• Lee MS1, Kim HS, Cho EK, et al. COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease. Neurology 2002;26:564–7.
   Google Scholar
• De Bonis ML, Tessitore A, Pellecchia MT, et al. Impaired transmethylation potential in Parkinson's disease patients treated with L–Dopa. Neurosci Lett 2010;468:287–91.
   PubMed Web of Science ®Google Scholar
• Todorovic Z, Dzoljic E, Novakovic I, et al. Homocysteine serum levels and MTHFR C67T genotype in patients with Parkinson's disease, with and without levodopa therapy. J Neurol Sci 2006;248:56–61.
   PubMed Web of Science ®Google Scholar
• Lamberti P, Zoccolella S, Iliceto G, et al. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Mov Disord 2005;20:69–72.
   PubMed Web of Science ®Google Scholar
• Becker ML, Visser LE, van Schaik RH, et al. OCT1 polymorphism is associated with response and survival time in anti–Parkinsonian drug users. Neurogenetics 2011;12:79–82.
   PubMed Web of Science ®Google Scholar
• Kaut O, Schmitt I, Wüllner U. DNA methylation in lymphocytes and brain samples of Parkinson's disease patients. J Mov Disord 2010;25:S613.
   Web of Science ®Google Scholar
• Morgante F, Espay AJ, Gunraj C, et al. Motor cortex plasticity in Parkinson's disease and L–DOPA–induced dyskinesias. Brain 2006;129:1059–69.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 2005;20(Suppl. 11):11–6.
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Korczyn AD, et al. Development of dyskinesias in a 5–year trial of ropinirole and L–DOPA. Mov Disord 2006;21:1844–50.
   PubMed Web of Science ®Google Scholar
• Chase TN, Oh JD. Striatal dopamine–and glutamate–mediated dysregulation in experimental parkinsonism. Trends Neurosci 2000;23:86–91.
   Web of Science ®Google Scholar
• Conn PJ, Battaglia G, Marino MJ, et al. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci 2005;6:787–98.
   PubMed Web of Science ®Google Scholar
• Oueslati A, Sgambato-Faure V, Melon C, et al. High–Frequency Stimulation of the Subthalamic Nucleus Potentiates L–DOPA–Induced Neurochemical Changes in the Striatum in a Rat Model of Parkinson's Disease. J Neurosci 2007;27:2377–86.
   PubMed Web of Science ®Google Scholar
• Gardoni F, Picconi B, Ghiglieri V, et al. A Critical Interaction between NR2B and MAGUK in L–DOPA Induced Dyskinesia. J. Neurosci 2006;26:2914–22.
   PubMed Web of Science ®Google Scholar
• Makoff AJ, Graham JM, Arranz MJ, et al. Association study of dopamine receptor gene polymorphisms with drug–induced hallucinations in patients with idiopathic Parkinson's disease. J Pharmacogenetics 2000;10:43–8.
   PubMedGoogle Scholar
• Wang J, Liu ZL, Chen B. Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD. Neurology 2001;56:1757–9.
   PubMed Web of Science ®Google Scholar
• Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum. Mutat 2004;23:540–5.
   PubMed Web of Science ®Google Scholar
• Paus S, Grünewald A, Klein C, et al. The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease. Mov Disord 2008;23:599–602.
   PubMed Web of Science ®Google Scholar
• Rieck M, Schumacher-Schuh AF, Altmann V, et al. DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients. Pharmacogenomics 2012;13:1701–10.
   PubMed Web of Science ®Google Scholar
• Strong JA, Dalvi A, Revilla FJ, et al. Genotype and smoking history affect risk of L–Dopa–induced dyskinesias in Parkinson's disease. Mov Disord 2006;21:654–9.
   PubMed Web of Science ®Google Scholar
• Kaplan N, Vituri A, Korczyn AD, et al. Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease. J Mol Neurosci 2014;53:183–8.
   PubMed Web of Science ®Google Scholar
• Berthet A, Porras G, Doudnikoff E, et al. Pharmacological Analysis Demonstrates Dramatic Alteration of D1 Dopamine Receptor Neuronal Distribution in the Rat Analog of L–DOPA–Induced Dyskinesia. J. Neurosci 2009;29:4829–35.
   PubMed Web of Science ®Google Scholar
• Paus S, Gadow F, Knapp M, et al. Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism. Mov Disord 2009;24:1080–4.
   PubMed Web of Science ®Google Scholar
• Dorszewska J, Prendecki M, Oczkowska A, et al. Polymorphism of the COMT, MAO, DAT, NET and 5-HTT Genes, and Biogenic Amines in Parkinson's Disease. Current Genomics 2013;14:518–33.
   PubMed Web of Science ®Google Scholar
• Kaiser R, Hofer A, Grapengiesser A, et al. L–Dopa–induced adverse effects in PD and dopamine transporter gene polymorphism. J Neurol 2003;60:1750–5.
   Google Scholar
• de Lau LM, Verbaan D, Marinus J, et al. Catechol-O-methyltransferase Val158Met and the risk of dyskinesias in Parkinson's disease. Mov Disord 2012;27:132–5.
   PubMed Web of Science ®Google Scholar
• Watanabe M, Harada S, Nakamura T, et al. Association between catechol-O-methyltransferase gene polymorphisms and wearing-off and dyskinesia in Parkinson's disease. Neuropsychobiology 2003;48:190–3.
   PubMed Web of Science ®Google Scholar
• Fumagalli F, Racagni G, Riva MA. Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease. Pharmacogenomics J 2006;6:95–104.
   PubMed Web of Science ®Google Scholar
• Moreau C, Destee A. A new perspective on brain derived neurotrophin factor polymorphism in L–DOPA induced dyskinesia. J Neurol Neurosurg Psychiatry 2009;80:129.
   PubMed Web of Science ®Google Scholar
• Fu Y, Zhao Y, Luan W, et al. Sigma–1 receptors amplify dopamine D1 receptor signaling at presynaptic sites in the prelimbic cortex. Biochim Biophys Acta 2010;12:1396–408.
   Web of Science ®Google Scholar
• Foltynie T, Cheeran B, Williams-Gray CH, et al. BDNF Val66Met influences time to onset of L–DOPA induced dyskinesia in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2009;80:141–4.
   Google Scholar
• Karakasis C, Kalinderi K, Katsarou Z, et al. Association of brain-derived neurotrophic factor (BDNF) Val66Met polymorphism with Parkinson's disease in a Greek population. J Clin Neurosci 2011;18:1744–5.
   PubMed Web of Science ®Google Scholar
• Gao L, Díaz-Corrales FJ, Carrillo F, et al. Brain derived neurotrophic factor G196A polymorphism and clinical features in Parkinson's disease. Acta Neurol Scand 2010;122:41–5.
   PubMed Web of Science ®Google Scholar
• Xu MQ, St Clair D, Feng GY, et al. BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine–induced extrapyramidal syndrome in the Chinese population. J. Pharmacogenetics Genomics 2008;18: 449–57.
   PubMed Web of Science ®Google Scholar
• Aebicher P. Effective delivery of the neuroprotectant to the brain. J Mov Disord 2010;25:S602.
   PubMed Web of Science ®Google Scholar
• Liu YZ, Tang BS, Yan XX, et al. Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients. Eur. J. Clin. Pharmacol 2009;65:679–83.
   PubMed Web of Science ®Google Scholar
• Goldman JG, Goetz CG, Berry-Kravis E, et al. Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. Arch Neurol 2004;61:1280–4.
   PubMed Web of Science ®Google Scholar
• Jian W, Yan-Mei S, Zhuo–Lin L, et al. Cholecystokinin, cholecystokinin–A receptor and cholecystokinin–B receptor gene polymorphisms in Parkinson's disease. J Pharmacogenetics 2003;13:365–9.
   PubMedGoogle Scholar
• De la Fuente–Fernández R, Nunez MA, Lopez E. The apolipoprotein E epsilon 4 allele increases the risk of drug–induced hallucinations in Parkinson's disease. Clin. Neuropharmacol 1999;22:226–30.
   PubMed Web of Science ®Google Scholar
• Feldman B, Chapman J, Korczyn AD. Apolipoprotein epsilon4 advances appearance of psychosis in patients with Parkinson's disease. Acta Neurol Scand 2006;113:14–7.
   PubMed Web of Science ®Google Scholar
• Inzelberg R, Paleacu D, Chapman J, et al. The apolipoprotein E epsilon4 allele increases the risk of drug–induced hallucinations in Parkinson's disease. Clin Neuropharmacol 2000;23:230–1.
   PubMed Web of Science ®Google Scholar
• Camicioli R, Rajput A, Rajput M, et al. Apolipoprotein E epsilon4 and catechol–O–methyltransferase alleles in autopsy–proven Parkinson's disease. Mol Cell Biochem 2008;312:131–8.
   PubMed Web of Science ®Google Scholar
• Lin JJ, Yueh KC, Lin SZ, et al. Genetic polymorphism of the angiotensin converting enzyme and L–DOPA–induced adverse effects in Parkinson's disease. J Neurol Sci 2007;252:130–4.
   PubMed Web of Science ®Google Scholar
• Rissling I, Korner Y, Geller F. Preprohypocretin polymorphisms in Parkinson disease patients reporting “sleep attacks”. Sleep 2005;28:871–5.
   PubMed Web of Science ®Google Scholar
• Frauscher B, Högl B, Maret S, et al. Association of daytime sleepiness with COMT polymorphism in patients with parkinson disease; a pilot study. Sleep 2004;27:733–6.
   PubMed Web of Science ®Google Scholar
• Paus S, Seeger G, Brecht HM, et al. Association study of dopamine D2, D3, D4 receptor and serotonin transporter gene polymorphisms with sleep attacks in Parkinson's disease. Mov Disord 2004;19:705–7.
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Bondon-Guitton E, Rascol O, et al. Adverse drug reactions to dopamine agonists: a comparative study in the french pharmacovigilance database. J Mov Disord 2010;25:1876–80.
   PubMed Web of Science ®Google Scholar
• Arbouw ME, Movig KL, Egberts TC, et al. Clinical and pharmacogenetic determinants for the discontinuation of non–ergoline dopamine agonists in Parkinson's disease. Eur J Clin Pharmacol 2009;65:1245–51.
   PubMed Web of Science ®Google Scholar
• Comings DE, Gade R, Wu S, et al. Studies of the potential role of the dopamine D1 receptor gene in addictive behaviors. Mol Psychiatry 1997;2:44–56.
   PubMed Web of Science ®Google Scholar
• da Silva Lobo DS1, Vallada HP, Knight J, et al. Dopamine genes and pathological gambling in discordant sib-pairs. J Gambl Stud 2007;23:421–33.
   PubMed Web of Science ®Google Scholar
• Kreek MJ, Nielsen DA, Butelman ER, et al. Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci 2005;8:1450–7.
   PubMed Web of Science ®Google Scholar
• Comings DE, Gade-Andavolu R, Gonzalez N, et al. The additive effect of neurotransmitter genes in pathological gambling. Clin Genet 2001;60:107–16.
   PubMed Web of Science ®Google Scholar
• Forbes EE, Brown SM, Kimak M, et al. Genetic variation in components of dopamine neurotransmission impacts ventral striatal reactivity associated with impulsivity. Mol Psychiatry 2009;14:60–70.
   PubMed Web of Science ®Google Scholar
• Retz W, Rösler M, Supprian T, et al. Dopamine D3 receptor gene polymorphism and violent behavior: relation to impulsiveness and ADHD-related psychopathology. J Neural Transm 2003;110:561–72.
   PubMed Web of Science ®Google Scholar
• Cormier F, Muellner J, Corvol JC. Genetics of impulse control disorders in Parkinson's disease. J Neural Transm 2013;120:665–71.
   PubMed Web of Science ®Google Scholar
• Van Tol HH, Wu CM, Guan HC, et al. Multiple dopamine D4 receptor variants in the human population. Nature 1992;358: 149–52.
   PubMed Web of Science ®Google Scholar
• Ebstein RP, Nemanov L, Klotz I, et al. Additional evidence for an association between the dopamine D4 receptor (D4DR) exon III repeat polymorphism and the human personality trait of novelty seeking. Mol Psychiatry 1997;2:472–7.
   PubMed Web of Science ®Google Scholar
• Eisenegger C, Knoch D, Ebstein RP, et al. Dopamine receptor D4 polymorphism predicts the effect of L-DOPA on gambling behavior. Biol Psychiatry 2010;67:702–6.
   PubMed Web of Science ®Google Scholar
• Pérez de Castro I1, Ibáñez A, Torres P, et al. Genetic association study between pathological gambling and a functional DNA polymorphism at the D4 receptor gene. Pharmacogenetics 1997;7:345–8.
   PubMedGoogle Scholar
• Kotler M, Cohen H, Segman R, et al. Excess dopamine D4 receptor (D4DR) exon III seven repeat allele in opioid-dependent subjects. Mol Psychiatry 1997;2:251–4.
   PubMed Web of Science ®Google Scholar
• Kim SI, Voshol H, van OJ, et al. Neuroproteomics: expression profiling of the brain's proteomes in health and disease. Neurochem Res 2004;29:1317–31.
   PubMed Web of Science ®Google Scholar
• Valastro B, Dekundy A, Krogh M, et al. Proteomic analysis of striatal proteins in the rat model of L–DOPA–induced dyskinesia. J Neurochem 2007;102:1395–409.
   PubMed Web of Science ®Google Scholar
• Gilgun-Sherki Y, Djaldetti R, Melamed E, et al. Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease. J Pharmacogenomics 2004;4:291–306.
   Google Scholar